{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Weerasekera L"],"funding":["Diabetes Australia Research Trust","National Center for Research Resources","AT and T","Royal Perth Hospital Medical Research Foundation","University of Western Australia","NCRR NIH HHS","National Heart, Lung, and Blood Institute","NIMH NIH HHS","Rebecca L. Cooper Medical Research Foundation","National Institute for Mental Health"],"pagination":["7281986"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5318628"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2017"],"pubmed_abstract":["Obesity is one of the most prevalent metabolic diseases in the Western world and correlates directly with insulin resistance, which may ultimately culminate in type 2 diabetes (T2D). We sought to ascertain whether the human metalloproteinase A Disintegrin and Metalloproteinase 19 (ADAM19) correlates with parameters of the metabolic syndrome in humans and mice. To determine the potential novel role of ADAM19 in the metabolic syndrome, we first conducted microarray studies on peripheral blood mononuclear cells from a well-characterised human cohort. Secondly, we examined the expression of ADAM19 in liver and gonadal white adipose tissue using an in vivo diet induced obesity mouse model. Finally, we investigated the effect of neutralising ADAM19 on diet induced weight gain, insulin resistance"],"journal":["Mediators of inflammation"],"pubmed_title":["ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice."],"pmcid":["PMC5318628"],"funding_grant_id":["R01 MH059490","C06 RR013556","S10 RR029392","HL045222","R37 MH059490","MH059490"],"pubmed_authors":["Schlaich M","Rudnicka C","Matthews VB","Goring HH","Curran JE","Johnson MP","Hricova J","Sang QX","Moses EK","Blangero J","Weerasekera L"],"additional_accession":[]},"is_claimable":false,"name":"ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice.","description":"Obesity is one of the most prevalent metabolic diseases in the Western world and correlates directly with insulin resistance, which may ultimately culminate in type 2 diabetes (T2D). We sought to ascertain whether the human metalloproteinase A Disintegrin and Metalloproteinase 19 (ADAM19) correlates with parameters of the metabolic syndrome in humans and mice. To determine the potential novel role of ADAM19 in the metabolic syndrome, we first conducted microarray studies on peripheral blood mononuclear cells from a well-characterised human cohort. Secondly, we examined the expression of ADAM19 in liver and gonadal white adipose tissue using an in vivo diet induced obesity mouse model. Finally, we investigated the effect of neutralising ADAM19 on diet induced weight gain, insulin resistance","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2026-05-30T14:25:56.922Z","creation":"2026-04-08T07:24:42.005Z"},"accession":"S-EPMC5318628","cross_references":{"pubmed":["28265178"],"doi":["10.1155/2017/7281986"]}}